ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ - First Disease-Modifying Treatment for AADC Deficiency
July 21, 2022 16:20 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
June 29, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces Receipt of MDSAP Certification
June 02, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
May 20, 2022 09:29 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annual Meeting in Washington, DC
May 13, 2022 09:25 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Reports First Quarter 2022 Results
May 11, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro and Higgs Boson Health Announce Collaboration
May 03, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1
April 28, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Expands Software License and Research Agreement with Philips to Power Expansion of the ClearPoint Platform into the Operating Room
April 27, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022
April 26, 2022 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...